Table 2 CAR T cell against AML target antigens
From: Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients
Target antigen | Clinical trial ID | Phase | Disease | Institution |
|---|---|---|---|---|
CD33 | NCT03126864 | I | R/R AML | University of Texas MD Anderson Cancer Center, Houston, Texas, United States |
NCT02799680 | I | R/R AML | Affiliated Hospital of Academy of Military Medical Sciences, Beijing, Beijing, China| Chinese PLA General Hospital, Beijing, Beijing, China | |
NCT01864902 | I/II | R/R AML | Biotherapeutic Department and Pediatrics Department of Chinese PLA General Hospital, Hematological Department, Affiliated Hospital of Changzhi Medical College, Beijing, Beijing, China | |
NCT02944162 | I/II | R/R AML | PersonGen BioTherapeutics (Suzhou) Co., Ltd., Suzhou, Jiangsu, China | |
NCT03291444 | I | R/R AML, MDS; ALL | Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China | |
NCT03473457 | n.a. | R/R AML | Southern Medical University Zhujiang Hospital, Guangdong, Guangdong, China | |
NCT03222674 | I/II | AML | Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong, China| | |
CD38 | NCT03291444 | I | R/R AML, MDS; ALL | Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China |
NCT03473457 | n.a | R/R AML | Southern Medical University Zhujiang Hospital, Guangdong, Guangdong, China | |
NCT03222674 | I/II | AML | Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong, China| | |
CD123 | NCT03585517 | I | AML | Xian Lu, Beijing, China |
NCT03114670 | I | Recurred AML after alloHSCT | Fengtai District, Beijing Shi, China | |
NCT03556982 | I/II | R/R AML | 307 Hospital of PLA, Beijing, Beijing, China | |
NCT02623582 | I | R/R AML | Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States | |
NCT02159495 | I | R/R AML | City of Hope Medical Center, Duarte, California, United States | |
NCT03672851 | I | R/R AML | Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China | |
NCT03766126 | I | R/R AML | University of Pennsylvania, Philadelphia, Pennsylvania, United States | |
NCT03291444 | I | R/R AML, MDS; ALL | Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China | |
NCT03473457 | n.a | R/R AML | Southern Medical University Zhujiang Hospital, Guangdong, Guangdong, China | |
NCT03796390 | I | R/R AML | Hebei Yanda Ludaopei Hospital Langfang, Hebei, China | |
NCT03222674 | I/II | AML | Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong, China | |
UCART123 | NCT03190278 | I | R/R AML | Dana-Farber Cancer Institute Boston, Massachusetts, United States Weill Medical College of Cornell University New York, New York, United States, MD Anderson Cancer Center Houston, Texas, United States |
NCT01864902 | I | R/R AML, high-risk AML | Weill Cornell Medical College, New York, New York, United States MD Anderson Cancer Center, Houston, Texas, United States | |
CD123/CLL1 | NCT03631576 | II/III | R/R AML | Fujian Medical University Union Hospital, Fuzhou, Fujian, China |
CD33/CLL1 | NCT03795779 | I | R/R AML, MDS, MPN, CML | The General Hospital of Western Theater Command Chengdu, China Peking University Shenzhen Hospital Shenzhen, China |
CCL1 | NCT03222674 | I/II | AML | Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong, China| Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China| Yunnan Cancer Hospital & The Third Affiliated Hospital of Kunming Medical University & Yunnan Cancer Center, KunMing, Yunnan, China |
Lewis Y | NCT01716364 | I | Myeloma, AML, MDS | Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia |
WT1 | NCT03291444 | I | R/R AML, ALL, MDS | Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China |
CD7/NK92 | NCT03018405 | I/II | R/R AML | PersonGen BioTherapeutics (Suzhou) Co., Ltd., Suzhou, Jiangsu, China |
NKG2D | NCT02203825 | I | AML, MDS-RAEB, MM | Dana-Farber Cancer Institute, Boston, Massachusetts, United States |
NCT03018405 | I/II | R/R AML, AML, Myeloma | Tampa, Florida, United States| Buffalo, New York, United States| Brussels, Belgium|Brussels, Belgium| Ghent, Belgium |